Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery
NCT ID: NCT00992355
Last Updated: 2009-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
97 participants
INTERVENTIONAL
2009-01-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day
* combination of tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day, plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three times/day. The topical treatment is administered for 28 days after phacoemulsification.
Patients are independently assessed by two ophthalmologists. On day 28, patients are evaluated for
* corneal edema
* conjunctival redness
* anterior chamber reaction. Moreover, the cases necessitating continuation of treatment are compared in the two groups on day 28 and 42.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery
NCT01103401
A Bioequivalence Study of Tobradex AF
NCT00362895
Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies
NCT00865540
A Bioequivalence Study to Compare the Pharmacokinetics (PK) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery
NCT02734459
A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)
NCT01023724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tobramycin 0.3% - Dexamethasone 0.1%
Tobramycin 0.3% - Dexamethasone 0.1%
Tobramycin-Dexamethasone plus Ketorolac tromethamine
Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tobramycin 0.3% - Dexamethasone 0.1%
Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Uneventful phacoemulsification surgery
Exclusion Criteria
* Age-related macular degeneration
* Proliferative diabetic retinopathy
* Glaucoma
55 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Veroia General Hospital
OTHER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Ophthalmology, Veroia General Hospital
Véroia, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VGH-EYE01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.